Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

This study is to assess how patients respond to their treatment for cervical cancer. This research does not involve a specific treatment for the cancer that will be recommended by the doctor and may include radiation therapy and/or chemotherapy. This is a separate research imaging study designed to assess how patients respond to their treatment for cervical cancer.

Inclusion Criteria:

• Biopsy-documented, newly-diagnosed primary cervical cancer of all histopathology types.
• Clinically visible gross lesion (International Federation of Gynecology and Obstetrics (FIGO) stage IB1 and above).
• Treatment (chemoradiation), DCE-MRI and 18F-FMISO PET studies will be at MSKCC.
• Patients must be an adult female 18 years of age or older.

Exclusion Criteria:

• Patients who because of general medical or psychiatric condition, or physiologic status cannot give an informed consent.
• Patients who received prior radiation treatment to pelvis.
• Patients with contraindications to DCE-MRI (non-compatible cardiac pacemakers or intracranial vascular clips, allergy to Gadolinium, end-stage renal disease) and/or 18F-FMISO PET.
• Patients who do not fulfill the screening criteria for safe DCE-MRI or 18F-FMISO PET as per the Department of Radiology guidelines.
• Pregnant patients; and or patients who are breast-feeding their babies.